Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 188re-lanreotide
2. 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
3. 3-(2-naphthyl)-d-ala-cys-tyr-d-trp-lys-val-cys-thr-nh2
4. 3-(2-naphthyl)alanyl-cystinyl-tyrosyl-tryptophyl-lysyl-valyl-cystinyl-threonine Amide
5. Angiopeptin
6. Bim 23014
7. Bim 23014 C
8. Bim 23014c
9. Bim-23014
10. Bim-23014 C
11. D-nal-cys-tyr-trp-lys-val-cys-thr-nh2
12. Dc 13-116
13. Dc-13-116
14. Dc13-116
15. L-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, Cyclic (2-7)-disulfide
16. Lanreotide
17. Lanreotide Acetate
18. Lanreotide-sr
19. Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-nh2
20. Nal-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2
21. Naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
22. Naphthyl-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2
23. Somatulin
24. Somatulina
25. Somatuline
1. Somatuline Lp
2. Lanreotide (acetate)
3. Bim-23014c
4. Ipstyl
5. Somatuline
6. Somatuline Autogel
7. 2378114-72-6
8. Angiopeptin Acetate
9. Somatulina
10. Somatuline La
11. Acetic Acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
12. Chembl1201184
13. Hy-p1959a
14. Itm-014
15. Mfcd00873576
16. Bn-52030
17. Dc13-116
18. Cs-0113779
19. P1088
| Molecular Weight | 1156.4 g/mol |
|---|---|
| Molecular Formula | C56H73N11O12S2 |
| Hydrogen Bond Donor Count | 14 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 17 |
| Exact Mass | 1155.48815915 g/mol |
| Monoisotopic Mass | 1155.48815915 g/mol |
| Topological Polar Surface Area | 443 Ų |
| Heavy Atom Count | 81 |
| Formal Charge | 0 |
| Complexity | 2030 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Somatuline depot |
| PubMed Health | Lanreotide (Subcutaneous) |
| Drug Classes | Endocrine-Metabolic Agent |
| Drug Label | Somatuline Depot (lanreotide) Injection 60, 90 and 120 mg is a prolonged-release formulation for deep subcutaneous injection containing the drug substance lanreotide acetate, a synthetic octapeptide with a biological activity similar to naturally occ... |
| Active Ingredient | Lanreotide acetate |
| Dosage Form | Injectable |
| Route | Subcutaneous |
| Strength | eq 90mg base; eq 120mg base; eq 60mg base |
| Market Status | Prescription |
| Company | Ipsen Pharma |
| 2 of 2 | |
|---|---|
| Drug Name | Somatuline depot |
| PubMed Health | Lanreotide (Subcutaneous) |
| Drug Classes | Endocrine-Metabolic Agent |
| Drug Label | Somatuline Depot (lanreotide) Injection 60, 90 and 120 mg is a prolonged-release formulation for deep subcutaneous injection containing the drug substance lanreotide acetate, a synthetic octapeptide with a biological activity similar to naturally occ... |
| Active Ingredient | Lanreotide acetate |
| Dosage Form | Injectable |
| Route | Subcutaneous |
| Strength | eq 90mg base; eq 120mg base; eq 60mg base |
| Market Status | Prescription |
| Company | Ipsen Pharma |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
API SUPPLIERS
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
Click Us!
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-04-03
Pay. Date : 2019-02-01
DMF Number : 33336
Submission : 2019-02-08
Status : Active
Type : II
Aspen API. More than just an API.
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39768
Submission : 2024-06-28
Status : Active
Type : II
Chunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.
NDC Package Code : 52076-6264
Start Marketing Date : 2019-10-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-02-13
Pay. Date : 2023-01-30
DMF Number : 36547
Submission : 2023-02-02
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-12-21
Pay. Date : 2015-09-15
DMF Number : 29693
Submission : 2016-08-16
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 120MG BAS...DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)
USFDA APPLICATION NUMBER - 215395
DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 60MG BASE...DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)
USFDA APPLICATION NUMBER - 215395
DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 90MG BASE...DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)
USFDA APPLICATION NUMBER - 215395
DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 120MG BAS...DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)
USFDA APPLICATION NUMBER - 22074
DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 60MG BASE...DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)
USFDA APPLICATION NUMBER - 22074
DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 90MG BASE...DOSAGE - SOLUTION;SUBCUTANEOUS - EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)
USFDA APPLICATION NUMBER - 22074
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
We have 15 companies offering Lanreotide
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
Market Place
